National Institutes of Health publish findings on Selumetinib positive outcomes in children with Neurofibromatosis type 1
On 18 March 2020 National Institutes of Health (NIH) published results of the trial that show that Selumetinib improves outcomes for children with Neurofibromatosis type 1. According to the announcement in the trial, Selumetinib shrank plexiform neurofibromas and children experienced reduced pain, improved function and better overall quality of life.
According to Brigitte Widemann, M.D., lead author of the study, “While this is not yet a cure, this treatment is shrinking tumors and it’s making children feel better and have a better quality of life.”
NFPU congratulates the whole team on their success and wishes them best luck in their future work!
The original source can be found here.
